Towards the development of DCIS risk prediction models
Fariba Behbod1, Seema Ahsan Khan2
1Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Cancer Cell
|December 13, 2022
Summary
Researchers identified an 812-gene classifier for high-risk ductal carcinoma in situ (DCIS) recurrence. This study also defines new DCIS subtypes, improving our understanding of this variable breast cancer condition.
Area of Science:
- Oncology
- Genomics
- Breast Cancer Research
Background:
- Ductal carcinoma in situ (DCIS) exhibits a variable natural history and poorly understood underlying biology.
- Accurate prognostication and subtype classification are crucial for effective DCIS management.
Purpose of the Study:
- To identify a gene classifier associated with high risk of DCIS recurrence.
- To define novel DCIS subtypes based on molecular characteristics.
Main Methods:
- Utilized two well-annotated DCIS patient repositories for comprehensive analysis.
- Employed genomic profiling to identify a specific 812-gene classifier.
Main Results:
- An 812-gene classifier was identified, demonstrating a strong association with increased risk of DCIS recurrence.
- Novel molecular subtypes of DCIS were defined, offering new insights into disease heterogeneity.
Conclusions:
- The identified gene classifier and novel subtypes provide valuable tools for risk stratification in DCIS.
- These findings pave the way for more personalized and targeted therapeutic strategies for DCIS patients.
